Literature DB >> 17152010

Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis.

Michael Hogardt1, Christina Hoboth, Sabine Schmoldt, Christine Henke, Lutz Bader, Jürgen Heesemann.   

Abstract

BACKGROUND: Pseudomonas aeruginosa (PA) strains with defective DNA mismatch repair genes generate numerous bacterial variants because of high mutation rates. In cystic fibrosis (CF), such mutator strains may lead to the rapid selection of survivors that are specifically adapted to the hostile environment of the inflamed CF lung.
METHODS: Genotypes and phenotypes of 111 PA variants descending from 3 distinct mutator strains obtained from 3 patients with CF were systematically characterized.
RESULTS: We demonstrated that PA mutS isolates accumulated in the CF lung during the observation period of 3-6 years, with dominance during the final stage of the disease. Mutator strains from the final stage of disease were multiresistant and had lost a set of established virulence-associated traits, including cytotoxicity for bronchial epithelial cells (Calu-3) and macrophages (J774). This pathoadaptation was associated with the loss of survival capacity in a typical environmental habitat, such as tap water. Strikingly, nonmutator strains that maintained their virulence potential persisted as a minority, probably with a preference for the lower airways.
CONCLUSIONS: Mutator strains may evolve from the initially infecting PA strain and generate numerous variants with a loss of destructive virulence factors, probably because of selection for improved survival in the deteriorated CF lung but at the expense of the ability to live freely.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17152010     DOI: 10.1086/509821

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

1.  Genotypic and phenotypic variation in Pseudomonas aeruginosa reveals signatures of secondary infection and mutator activity in certain cystic fibrosis patients with chronic lung infections.

Authors:  Ashley E Warren; Carla M Boulianne-Larsen; Christine B Chandler; Kami Chiotti; Evgueny Kroll; Scott R Miller; Francois Taddei; Isabelle Sermet-Gaudelus; Agnes Ferroni; Kathleen McInnerney; Michael J Franklin; Frank Rosenzweig
Journal:  Infect Immun       Date:  2011-09-19       Impact factor: 3.441

2.  Increased susceptibility to colistin in hypermutable Pseudomonas aeruginosa strains from chronic respiratory infections.

Authors:  M D Maciá; A Mena; N Borrell; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2007-09-24       Impact factor: 5.191

3.  Chronic Airway Colonization by Achromobacter xylosoxidans in Cystic Fibrosis Patients Is Not Sustained by Their Domestic Environment.

Authors:  Chloé Dupont; Estelle Jumas-Bilak; Clara Doisy; Fabien Aujoulat; Raphaël Chiron; Hélène Marchandin
Journal:  Appl Environ Microbiol       Date:  2018-11-15       Impact factor: 4.792

Review 4.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 5.  Hypermutation and stress adaptation in bacteria.

Authors:  R Jayaraman
Journal:  J Genet       Date:  2011-08       Impact factor: 1.166

6.  Hypermutator Pseudomonas aeruginosa Exploits Multiple Genetic Pathways To Develop Multidrug Resistance during Long-Term Infections in the Airways of Cystic Fibrosis Patients.

Authors:  C A Colque; A G Albarracín Orio; S Feliziani; R L Marvig; A R Tobares; H K Johansen; S Molin; A M Smania
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

7.  General and inducible hypermutation facilitate parallel adaptation in Pseudomonas aeruginosa despite divergent mutation spectra.

Authors:  Michael R Weigand; George W Sundin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-06       Impact factor: 11.205

8.  Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.

Authors:  Cornelia B Landersdorfer; Vanessa E Rees; Rajbharan Yadav; Kate E Rogers; Tae Hwan Kim; Phillip J Bergen; Soon-Ee Cheah; John D Boyce; Anton Y Peleg; Antonio Oliver; Beom Soo Shin; Roger L Nation; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

9.  Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.

Authors:  V Plasencia; N Borrell; M D Maciá; B Moya; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

10.  Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients.

Authors:  David A D'Argenio; Manhong Wu; Lucas R Hoffman; Hemantha D Kulasekara; Eric Déziel; Eric E Smith; Hai Nguyen; Robert K Ernst; Theodore J Larson Freeman; David H Spencer; Mitchell Brittnacher; Hillary S Hayden; Sara Selgrade; Mikkel Klausen; David R Goodlett; Jane L Burns; Bonnie W Ramsey; Samuel I Miller
Journal:  Mol Microbiol       Date:  2007-04       Impact factor: 3.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.